company
Mukesh B. Chandre, M.D., MBBS/Ashirwad Hospital & Research Centre
Industry: pharmaceutical
Jurisdiction: US
FDA Warning Letter timeline
V1 scope: FDA Warning Letters only. Additional public-record sources (SEC, CPSC, federal contracts) are on the V2 roadmap and are not surfaced here today.
- fda_warning_letter · warning_letter2026-04-29Mukesh B. Chandre, M.D., MBBS/Ashirwad Hospital & Research Centre — In Vivo Bioavailability-Bioequivalence Studies – Clinical (2026-04-29)
Frequently asked questions
- How many FDA warning letters has Mukesh B. Chandre, M.D., MBBS/Ashirwad Hospital & Research Centre received?
- Argus HQ has recorded 1 FDA warning letter for Mukesh B. Chandre, M.D., MBBS/Ashirwad Hospital & Research Centre.
- What FDA recalls has Mukesh B. Chandre, M.D., MBBS/Ashirwad Hospital & Research Centre issued?
- Argus HQ has not recorded an FDA recall tied to Mukesh B. Chandre, M.D., MBBS/Ashirwad Hospital & Research Centre in our current dataset.
- Is Mukesh B. Chandre, M.D., MBBS/Ashirwad Hospital & Research Centre FDA compliant?
- Argus HQ is not a compliance rating service. As of this page's last update, our dataset shows 1 warning letter, 0 recalls, and 0 approval records for Mukesh B. Chandre, M.D., MBBS/Ashirwad Hospital & Research Centre. Review the linked FDA source records directly before drawing a compliance conclusion.
Informational only. FDA Warning Letters are public records (17 USC §105). Summaries are AI-assisted and may contain errors; always verify against the original FDA letter before acting. Not legal, financial, or regulatory advice.